Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022
Waltham, Mass., September 27, 2022 (BUSINESS WIRE) — Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, today announced that Gilles Gallant, BPharm, PhD, FOPQ, Chief Development Officer, has received the George R. Pettit Individual Input to the Field Award for 2022. The award was presented at the 13th World Antibody Drug Conjugate Conference, held this month in San Diego.
“While this award recognizes individual contributions to the ADC field, drug development is a team sport,” said Dr. Gallant. “It requires strong collaboration between many functions, including discovery, pre-clinical, pharmacology, toxicology, CMC, clinical operations, oncology clinical development, regulatory affairs, biostatistics, data management, and many more. I am grateful to the teams I have led, and feel that my colleagues share in the honor.”
The George R. Pettit Award is granted annually during the World ADC Conference in memory of one of the field’s pioneers. The award serves to recognize recent successes, long-term commitment to the field and those who have gone above and beyond to ensure the continued success of the ADC field and bring more life changing drugs to patient’s hands.
“All of us at Mythic Therapeutics are proud of Gilles and his significant accomplishments,” said Brian Fiske, PhD, Co-founder and Chief Scientific Officer. “The George R. Pettit Award is wonderful recognition of his contributions to the field of antibody-drug conjugates, and we are fortunate that he is leading the clinical development of our lead program in lung cancer as well as our broader product pipeline.”
About George R. Pettit
George R. Pettit was a Regents’ Professor in Chemistry in the School of Molecular Sciences at Arizona State University. He was a pioneer in research leading to cancer therapies derived from marine organisms, as well as insects and plants. Pettit and his team synthesized synthetic analogs of auristatins including monomethyl auristatin E (MMAE), which proved to be an invaluable warhead for a range of antibody-drug conjugates (ADCs), several of which have been approved by the FDA for the treatment of a range of cancers. His many awards include the Outstanding Investigator Award from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic’s ADCs. The Company’s major investors include Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com